Galectin Therapeutics (GALT) Preferred Shares (2010 - 2026)
Galectin Therapeutics' quarterly Preferred Shares came in at $480000.0 in Q1 2026, down 4.0% year-on-year from $500000.0 in Q1 2025, and down 2.04% quarter-over-quarter from $490000.0 in Q4 2025.
Galectin Therapeutics has reported Preferred Shares for 17 years, with the latest figure at $480000.0 in Q1 2026.
- For the quarter ending Q1 2026, Preferred Shares fell 4.0% year-over-year to $480000.0; the trailing twelve-month figure through Mar 2026 stood at $480000.0 (down 4.0% YoY), and the FY2025 full-year result was $490000.0, down 2.0% from the prior year.
- Preferred Shares for Q1 2026 stood at $480000.0, down from $490000.0 in the prior quarter.
- The five-year high for Preferred Shares was $527000.0 in Q1 2022, with the low at $480000.0 in Q1 2026.
- Average Preferred Shares over 5 years is $502176.5, with a median of $500000.0 recorded in 2023.
- Year-over-year, Preferred Shares changed 0.0% in 2022 and decreased 4.0% in 2026.
- Tracing GALT's Preferred Shares over 5 years: stood at $510000.0 in 2022, then fell by 1.96% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then declined by 2.0% to $490000.0 in 2025, then decreased by 2.04% to $480000.0 in 2026.
- The last three Preferred Shares figures came in at $480000.0 (Q1 2026), $490000.0 (Q4 2025), and $490000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | 480,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 480,000.00 |
| Dec 31, 2025 | 490,000.00 |
| Sep 30, 2025 | 490,000.00 |
| Jun 30, 2025 | 490,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Dec 31, 2023 | 500,000.00 |
| Sep 30, 2023 | 510,000.00 |
| Jun 30, 2023 | 510,000.00 |
| Mar 31, 2023 | 510,000.00 |
| Dec 31, 2022 | 510,000.00 |
| Sep 30, 2022 | 510,000.00 |
| Jun 30, 2022 | 510,000.00 |
| Mar 31, 2022 | 527,000.00 |
| Dec 31, 2021 | 527,000.00 |
| Sep 30, 2021 | 527,000.00 |
| Jun 30, 2021 | 527,000.00 |
| Mar 31, 2021 | 527,000.00 |
| Dec 31, 2020 | 527,000.00 |
| Sep 30, 2020 | 527,000.00 |
| Jun 30, 2020 | 537,000.00 |
| Mar 31, 2020 | 537,000.00 |
| Dec 31, 2019 | 537,000.00 |
| Sep 30, 2019 | 537,000.00 |
| Mar 31, 2019 | 537,000.00 |
| Dec 31, 2018 | 537,000.00 |
| Sep 30, 2018 | 547,000.00 |
| Jun 30, 2018 | 3.70 Mn |
| Mar 31, 2018 | 1.22 Mn |
| Dec 31, 2017 | 3.70 Mn |
| Sep 30, 2017 | 1.76 Mn |
| Jun 30, 2017 | 1.76 Mn |
| Mar 31, 2017 | 1.22 Mn |
| Dec 31, 2016 | 1.22 Mn |
| Sep 30, 2016 | 610,000.00 |
| Jun 30, 2016 | 557,000.00 |
| Mar 31, 2016 | 557,000.00 |
| Dec 31, 2015 | 557,000.00 |
| Sep 30, 2015 | 557,000.00 |
| Jun 30, 2015 | 567,000.00 |
| Mar 31, 2015 | 567,000.00 |
| Dec 31, 2014 | 567,000.00 |
| Sep 30, 2014 | 567,000.00 |
| Jun 30, 2014 | 567,000.00 |
| Mar 31, 2014 | 587,000.00 |
| Dec 31, 2013 | 587,000.00 |
| Sep 30, 2013 | 632,000.00 |
| Jun 30, 2013 | 632,000.00 |
| Mar 31, 2013 | 632,000.00 |
| Dec 31, 2012 | 632,000.00 |
| Sep 30, 2012 | 632,000.00 |
| Jun 30, 2012 | 632,000.00 |
| Mar 31, 2012 | 632,000.00 |
| Dec 31, 2011 | 632,000.00 |
| Sep 30, 2011 | 632,000.00 |
| Jun 30, 2011 | 632,000.00 |
| Dec 31, 2010 | 644,000.00 |